Houston wealth management adviser shares strategies for starting a successful business

guest column

Here's what this wealth management adviser wants you to know before you start your business. Photo via Getty Images

May is Small Business Appreciation month and as a Houstonian, small business owner and wealth management advisor, I understand firsthand the questions, considerations and challenges involved with navigating the nuanced world of small business ventures.

In 2005, I started RSF Wealth Management with my business partner. RSF Wealth Management is a Houston-based firm of Northwestern Mutual focused on comprehensive, collaborative and educational financial planning.

Understanding that every startup is different, I believe there are a few key strategies to keep in mind when starting a business.

1. Create a comprehensive business plan

Any lucrative, viable business has to start with a good plan that outlines what you will need to grow revenue and thrive long-term. Creating this strategic business outline will serve as a roadmap for your beginning years as well as a marketing tool when finding investors. The business plan should highlight what your outlook is for the next five years, how you will leverage your product to make profit, and how much money you will need to achieve and maintain financial success—no matter what scenario may come your way.

2. Establish a solid financial foundation

As most startup businesses take up to five years to turn over profit, it is important to receive funding or set aside extra cash, even if it’s a small amount. My advice to small business owners is to make sure you have at least six months to a years’ worth of liquidity before starting a business venture. Emergency savings funds and other cash reserves can help to cover the operational and overhead costs to startups. If you don’t have enough in your personal savings or cash reserves, there are loan options for small businesses, including the paycheck protection program loan, economic injury disaster loan, traditional SBA 7(A) loan and SBA express bridge loan.

3. Verify everything is documented

Documenting everything is crucial when building the foundation of your business for both legal and tax purposes. Not only will this help if something goes wrong with your business, but it will also keep formal structure between you and your business partner. All startups should complete a buy-sell agreement, which details how your partners’ share will be obtained by the remaining partners in case of their death or leave. I also recommend filing a morality clause contract, which requires all employees to comply to behavioral standards during the life of their contract.

4. Review your insurance and tax options

Small business owners should be regularly reviewing their tax and insurance options to ensure they are updated to reflect changing business needs. For instance, the SECURE Act 2.0 tax credit is a new incentive designed to make it easy and affordable for small businesses to offer employer-sponsored retirement plans. The new legislation allows increased tax credits to small businesses to encourage plan sponsorship and improve retirement readiness.

Additionally, business insurance for startups can help cover costs associated with property damage or liability claims. For example, disability overhead expense insurance provides your business with money to pay for everyday operational expenses in the event you’re unable to work due to an illness or injury. Generally, if you provide coverage for employees and cover the premium, you will be able to deduct those costs as a business expense.

Despite the difficulties of making the jump from employee to entrepreneur, 5 million new businesses were created in 2022 according to a study by the US Census Bureau. New businesses are being created every day and with the excitement of starting a new business also comes the complexities and challenges associated with a new business venture.

Financial advisors and industry experts can help you create a plan, understand what loan option is right for you and how much you will need to have in cash reserves to ensure you can securely and stably run your new business. No matter the size or operation of your business, financial advisors can help document your finances and connect you with the right attorney or accountant to set you up for long-term success.

------

Keith Rollins is a wealth management advisor with Northwestern Mutual and a founding partner of RSF Wealth Management.

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Property Showcase

Greentown Labs names Lawson Gow as its new Houston leader

head of hou

Greentown Labs has named Lawson Gow as its Head of Houston.

Gow is the founder of The Cannon, a coworking space with seven locations in the Houston area, with additional partner spaces. He also recently served as managing partner at Houston-based investment and advisory firm Helium Capital. Gow is the son of David Gow, founder of Energy Capital's parent company, Gow Media.

According to Greentown, Gow will "enhance the founder experience, cultivate strategic partnerships, and accelerate climatetech solutions" in his new role.

“I couldn’t be more excited to join Greentown at this critical moment for the energy transition,” Gow said in a news release. “Greentown has a fantastic track record of supporting entrepreneurs in Houston, Boston, and beyond, and I am eager to keep advancing our mission in the energy transition capital of the world.”

Gow has also held analyst, strategy and advising roles since graduating from Rice University.

“We are thrilled to welcome Lawson to our leadership team,” Georgina Campbell Flatter, CEO of Greentown Labs, added in the release. “Lawson has spent his career building community and championing entrepreneurs, and we look forward to him deepening Greentown’s support of climate and energy startups as our Head of Houston.”

Gow is the latest addition to a series of new hires at Greentown Labs following a leadership shakeup.

Flatter was named as the organization's new CEO in February, replacing Kevin Dutt, Greentown’s interim CEO, who replaced Kevin Knobloch after he announced that he would step down in July 2024 after less than a year in the role.

Greentown also named Naheed Malik its new CFO in January.

Timmeko Moore Love was named the first Houston general manager and senior vice president of Greentown Labs. According to LinkedIn, she left the role in January.

---

This article originally appeared on our sister site, EnergyCapitalHTX.com.

Houston foundation grants $27M to support Texas chemistry research

fresh funding

Houston-based The Welch Foundation has doled out $27 million in its latest round of grants for chemical research, equipment and postdoctoral fellowships.

According to a June announcement, $25.5 million was allocated for the foundation's longstanding research grants, which provide $100,000 per year in funding for three years to full-time, regular tenure or tenure-track faculty members in Texas. The foundation made 85 grants to faculty at 16 Texas institutions for 2025, including:

  • Michael I. Jacobs, assistant professor in the chemistry and biochemistry department at Texas State University, who is investigating the structure and thermodynamics of intrinsically disordered proteins, which could "reveal clues about how life began," according to the foundation.
  • Kendra K. Frederick, assistant professor in the biophysics department at The University of Texas Southwestern Medical Center, who is studying a protein linked to Parkinson’s disease.
  • Jennifer S. Brodbelt, professor in chemistry at The University of Texas at Austin, who is testing a theory called full replica symmetry breaking (fullRSB) on glass-like materials, which has implications for complex systems in physics, chemistry and biology.

Additional funding will be allocated to the Welch Postdoctoral Fellows of the Life Sciences Research Foundation. The program provides three-year fellowships to recent PhD graduates to support clinical research careers in Texas. Two fellows from Rice University and Baylor University will receive $100,000 annually for three years.

The Welch Foundation also issued $975,000 through its equipment grant program to 13 institutions to help them develop "richer laboratory experience(s)." The universities matched funds of $352,346.

Since 1954, the Welch Foundation has contributed over $1.1 billion for Texas-nurtured advancements in chemistry through research grants, endowed chairs and other chemistry-related ventures. Last year, the foundation granted more than $40.5 million in academic research grants, equipment grants and fellowships.

“Through funding basic chemical research, we are actively investing in the future of humankind,” Adam Kuspa, president of The Welch Foundation, said the news release. “We are proud to support so many talented researchers across Texas and continue to be inspired by the important work they complete every day.”

New Houston biotech co. developing capsules for hard-to-treat tumors

biotech breakthroughs

Houston company Sentinel BioTherapeutics has made promising headway in cancer immunotherapy for patients who don’t respond positively to more traditional treatments. New biotech venture creation studio RBL LLC (pronounced “rebel”) recently debuted the company at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago.

Rima Chakrabarti is a neurologist by training. Though she says she’s “passionate about treating the brain,” her greatest fervor currently lies in leading Sentinel as its CEO. Sentinel is RBL’s first clinical venture, and Chakrabarti also serves as cofounder and managing partner of the venture studio.

The team sees an opportunity to use cytokine interleukin-2 (IL-2) capsules to fight many solid tumors for which immunotherapy hasn't been effective in the past. “We plan to develop a pipeline of drugs that way,” Chakrabarti says.

This may all sound brand-new, but Sentinel’s research goes back years to the work of Omid Veiseh, director of the Rice Biotechnology Launch Pad (RBLP). Through another, now-defunct company called Avenge Bio, Veiseh and Paul Wotton — also with RBLP and now RBL’s CEO and chairman of Sentinel — invested close to $45 million in capital toward their promising discovery.

From preclinical data on studies in mice, Avenge was able to manufacture its platform focused on ovarian cancer treatments and test it on 14 human patients. “That's essentially opened the door to understanding the clinical efficacy of this drug as well as it's brought this to the attention of the FDA, such that now we're able to continue that conversation,” says Chakrabarti. She emphasizes the point that Avenge’s demise was not due to the science, but to the company's unsuccessful outsourcing to a Massachusetts management team.

“They hadn't analyzed a lot of the data that we got access to upon the acquisition,” explains Chakrabarti. “When we analyzed the data, we saw this dose-dependent immune activation, very specific upregulation of checkpoints on T cells. We came to understand how effective this agent could be as an immune priming agent in a way that Avenge Bio hadn't been developing this drug.”

Chakrabarti says that Sentinel’s phase II trials are coming soon. They’ll continue their previous work with ovarian cancer, but Chakrabarti says that she also believes that the IL-2 capsules will be effective in the treatment of endometrial cancer. There’s also potential for people with other cancers located in the peritoneal cavity, such as colorectal cancer, gastrointestinal cancer and even primary peritoneal carcinomatosis.

“We're delivering these capsules into the peritoneal cavity and seeing both the safety as well as the immune activation,” Chakrabarti says. “We're seeing that up-regulation of the checkpoint that I mentioned. We're seeing a strong safety signal. This drug was very well-tolerated by patients where IL-2 has always had a challenge in being a well-tolerated drug.”

When phase II will take place is up to the success of Sentinel’s fundraising push. What we do know is that it will be led by Amir Jazaeri at MD Anderson Cancer Center. Part of the goal this summer is also to create an automated cell manufacturing process and prove that Sentinel can store its product long-term.

“This isn’t just another cell therapy,” Chakrabarti says.

"Sentinel's cytokine factory platform is the breakthrough technology that we believe has the potential to define the next era of cancer treatment," adds Wotton.

View All Listings